Novavax has announced that it has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). The ruling relates to the updated version of its Covid-19 vaccine, NVX-CoV2705. This news follows similar decisions from the FDA regarding vaccines from Moderna and Pfizer/BioNTech.
By receiving EUA approval, the NVX-CoV2705 vaccine can be used for individuals 12 years and older. Novavax’s vaccine includes a monovalent component against the Omicron variant JN.1 strain of SARS-CoV-2.
John C Jacobs, CEO of Novavax said: “Our updated vaccine targets JN.1, the ‘parent strain’ of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.”
The latest wave of Covid-19 vaccine approvals follows the FDA’s Vaccines and Related Biological Products Advisory Committee’s vote on recommending a monovalent JN.1-lineage vaccine composition, with the new 2024-2025 vaccine formula being monovalent JN.1 vaccines.
